Clinical Neuroscience

[Chronic recurrent transverse myelitis or multiple sclerosis]

UNGUREÁN Aurélia1, PÁLFI Sándor1, DIBÓ György1, VÉCSEI László1

NOVEMBER 20, 1994

Clinical Neuroscience - 1994;47(11-12)

[The simultaneous appearance of multiple sclerosis and transverse myelitis is a known phenomenon. Apart from the appearance of spinal symptoms, other neurological signs of the brain involvement can urually be found, MRI shows disseminated foci in the brain. The positive evoked responses, the immunological abnormalities of the CSF, and the oligoclonality together prove the presence of multiple sclerosis. In these cases the symptoms of transverse myelitis may precede other signs of multiple sclerosis, or appear separately as a relapse. Recurrent transverse myelitis as an independent entity with negative MRI and CSF immunology, is an exciting topic concerning the etiologic factors and therapeutical considerations. Tvolging from the literature, the appearance of transverse myelitis as an independent entity, is rather rare. Details are given of a female patient with recurrent spinal cord signs, negative MRI and CSF immunology. During her ten-year follow-up no, symptoms of multiple sclerosis have developed. Further studies are needed to clarify the etiological factors, pathomechanism and therapeutic considerations of this relatively new and probably independent clinical entity.]


  1. Szent-Györgyi Albert Orvostudományi Egyetem Idegklinika, Szeged



Further articles in this publication

Clinical Neuroscience

[Clinico-morphological correlation in common dementias]

PAPP I. Mátyás

[ln the late sixties the revelation that more than half of the dementia cases in elderly people were caused by Alzheimer's disease and not by „cerebral arteriosclerosis" gave dementia research a new impetus, which accelerated in the eighties and has nowadays become explosive and has supplied us with a mass of data almost beyond comprehension. Nevertheless, even though it is most intensively, studied elucidation of the etiology and pathogenesis of the Alzheimer' s disease is still not expectable in the near future. ln addition to Alzheimer's disease, new results basically changing our views, have been achieved in the field of the vascular dementia and in dementias with Parkinsonian syndrome. Frontostriatal circuits discovered recently have helped our understanding of the subcortical dementia in these diseases and in others. By means of neuroimaging techniques, several dementia syndromes - paramedian thalamic infarcts, the watershed infarcts and the so called Binswanger's disease - have turned out to be much more common than previously believed. Clinicopathological observations have verified the role of the damage to the limbic and paralimbic structures, frontostriatal circuits and association pathways in the pathomechanism of dementias. ]

Clinical Neuroscience

[Typical behavior models of dealing with epilepsy - the models present between patient and members of the family]


[Four are main symptom groups described which were previously considered to be not more than an organic consequence of epilepsy. In most cases in the background of these groups a pathogenic/ pathogenetic role of typical relationship constellations between the patient and his/her relatives can be observed. These constellations are illustrated by case descriptions. It is pointed out that: 1. Epilepsy is a chronic illness in the course of which in every case certain psychodynamic events take place between the patient and his or her relatives in the immediate environment. 2. According to the present „neurological" approach and to the social expectations in the course of the patients' care the main stress is on biological events and changes. As a result intrapsychic and social-psychiatric motives are frequently manifested in the form of biological symptoms, too. 3. It follows from the above that the psychic constellation is interiorized by the patient and then he/she expresses it through somatic symptoms. At first sight these symptoms seem to be typical epileptic problems”. In actual fact, somatic „epileptologic” treatment cannot be regarded as succesful. 4. Since care is mainly based on auto- and heteroanamnestic data the phenomena discussed earlier could be highlighted only by means of the simultanious exploration of the family in question and by possible disagreement between the patient and his/her environment. 5. In order to treat the epileptic patient it is essential to consider the illness in relation to the patient and the members of the family.]

Clinical Neuroscience

[Characteristics of gadolinium-enhancement in ischemic stroke]

BARSI Péter, KENÉZ József, NAGY Zoltán, KULIN Árpád

[Stroke is a clinical diagnosis. In acute stroke, CT is the first examination of choice to exclude hemorrhage. In ischemic stroke, MR detects the changes earlier and more exactly, than CT. Contrast-enhanced MR imaging shows specific enhancement phenomena, viz. Intravasal high signal in the vessels of the ischemic cerebral region, meningeal enhancement, transitorial, mixed type enhancement and parenchymal enhancement. Our paper is deals with the causes and diagnostic significance of the different types of these enhancement effects, and discusses some differential diagnostic conclusions. In the near future, after installing more modern MR equipment, a more exact knowledge of the pathomechanism of stroke and, as a consequence, new and more effective therapies can be expected.]

Clinical Neuroscience

[Determination of serum C-reactive protein in the illnesses of central nervous system]


[Serum quantitative C-reactive protein concentrations were measured in 186 patients admitted with suspected neuroinfection or symptoms of other diseases in the central nervous system. The diagnoses were purulent meningitis (102), abscessus cerebri (5), meningitis basilaris (2), meningitis cryptococcica (1), sepsis (11), encephalitis (22), encephalopathia (5), autoimmune central nervous illness/disease/disorder (22), non-inflammatory central nervous disease/ disorder (12) and tumour cerebri (4). The highest values of C-reactive protein were measured in patients suffering from abscessus cerebri (250.8 +/ 64.2 mg/l), sepsis (221 +/- 16.4 mg/l) and purulent meningitis (153.0 +/- 94.59 mg/l). Serum C-reactive protein concentrations were moderately increased in viral infections (36.8 +/- 36 mg/l). The C-reactive protein level in the normal range in patients suffering from non-inflammatory and autoimmune central nervous illnesses/diseases/ disorders (4.0 +/- 1.5 mg/l or 10.0 +/- 18.5 mg/l). During our examinations the C-reactive protein levels showed both local and septicaemic reactions. C-reactive protein is considered as a valuable laboratory parameter both in diagnosings central nervous system diseases with suspected bacterial infection and in monitoring therapeutic efficiency.]

Clinical Neuroscience

[Trial to verify the link between onset of epileptic seizures and complex meteorological changes, pilot study]


[In this pilot study parameters are found that suggest a possible link between the onset of epileptic seizures and meteorological changes. The meteorological conditions were divided into 7 different levels in terms of their sympathetic/ parasympathetic effect and were related to the onset of 816 epileptic seizures of 15 patients. The possible epileptogenic effect of rapid (within 12 hours) meteorological changes was also evaluated and 48-hour periods before and after a given seizure were also considered. A trend was found in the distribution: within two days preceding seizures parasympathetic effects tended to be predominant, within those following seizures sympathetic effects tended to dominate. Surprisingly, rapid meteorological changes did not play significant role. More essential data were obtain in individual evaluations. In just every 4th patient the sympathetic or the parasympathetic effect was predominant before the seizure onset and in just every 3rd person rapid meteorological changes culminated in the pre- or in the post-seizure 48-hour interval. The most frequently occuring meteorological effect on the day of seizures was sympathetic. It is thought that these parameters might be appropriate to demonstrate the possible link. Even so, preference is given to individual evaluation which might have an additional therapeutic significance, too.]

All articles in the issue

Related contents

Clinical Neuroscience

Matrix metalloproteinases and their tissue inhibitors in relapsing remitting multiple sclerosis: Possible markers and treatment agents


Matrix metalloproteinases (MMPs), which are synthesized by many cell groups and responsible for the destruction of matrix proteins, and endogen tissue inhibitors of MMPs (TIMPs) have a role in the pathogenesis of Multiple Sclerosis (MS) by affecting the blood-brain barrier. We aimed to investigate the role of MMPs and TIMPs in the immunopathogenesis and in the course of multiple sclerosis (MS). We enrolled 25 relapsing remitting MS patients, who had a definite MS diagnosis according to McDonald criteria and 25 healthy subjects similar for age and gender as control group. MMP-9- and TIMP-1 levels were measured twice in patient group (one time during an attack and one in remission) and once in healthy subjects. MMP-9- and TIMP-levels of patients during attack and remission period and MMP-9/TIMP-1 ratio were found significantly higher than in the control subjects. In patient group MMP-9 and TIMP-1 levels and MMP-9/TIMP-1 ratio during attacks were not significantly different than during remission period. However, when subdivided according to their number of attacks, patients with 2 attacks had significantly higher levels during attack period comparing to remission period (p<0.05); in case of patients with more than 2 attacks did not have a statistically significant difference in attack and remission periods. Matrix metalloproteinases are important actors in MS immunopathogenesis, particularly in the early period and inhibitor agents for these enzymes can be used as a treatment option.

Clinical Neuroscience

[Family planning in multiple sclerosis: conception, pregnancy, breastfeeding]

RÓZSA Csilla

[Family planning is an exceptionally important question in multiple sclerosis, as women of childbearing age are the ones most often affected. Although it is proven that pregnancy does not worsen the long-term prognosis of relapsing-remitting multiple sclerosis, many patients are still doubtful about having children. This question is further complicated by the fact that patients – and often even doctors – are not sufficiently informed about how the ever-increasing number of available disease-modifying treatments affect pregnancies. Breastfeeding is an even less clear topic. Patients usually look to their neurologists first for answers concerning these matters. It falls to the neurologist to rationally evaluate the risks and benefits of contraception, pregnancy, assisted reproduction, childbirth, breastfeeding and disease modifying treatments, to inform patients about these, and then together come to a decision about the best possible therapeutic approach, taking the patients’ individual family plans into consideration. Here we present a review of relevant literature adhering to international guidelines on the topics of conception, pregnancy and breastfeeding, with a special focus on the applicability of approved disease modifying treatments during pregnancy and breastfeeding. The goal of this article is to provide clinicians involved in the care of MS patients with up-to-date information that they can utilize in their day-to-day clinical practice. ]

Clinical Neuroscience

[Health status and costs of ambulatory patients with multiple sclerosis in Hungary]

KOMOLY Sámuel, PÉNTEK Márta, GULÁCSI László, BRODSZKY Valentin, RÓZSA Csilla, SIMÓ Magdolna, ILJICSOV Anna

[Background and purpose - Data on disease burden of multiple sclerosis from Eastern-Central Europe are very limited. Our aim was to explore the quality of life, resource utilisation and costs of ambulating patients with multiple sclerosis in Hungary. Methods - Cross-sectional questionnaire survey was performed in two outpatient neurology centres in 2009. Clinical history, health care utilisation in the past 12 months were surveyed, the Expanded Disability Status Scale and the EQ-5D questionnaires were applied. Cost calculation was conducted from the societal perspective. Results - Sixty-eight patients (female 70.6%) aged 38.0 (SD 9.1) with disease duration of 7.8 (SD 6.7) years were involved. Fifty-five (80.9%) had relapsing-remitting form and 52 (76.5%) were taking immunomodulatory drug. The average scores were: Expanded Disability Status Scale 1.9 (SD 1.7), EQ-5D 0.67 (SD 0.28). Mean total cost amounted to 10 902 Euros/patient/year (direct medical 67%, direct nonmedical 13%, indirect costs 20%). Drugs, disability pension and informal care were the highest cost items. Costs of mild (Expanded Disability Status Scale 0-3.5) and moderate (Expanded Disability Status Scale 4.0-6.5) disease were 9 218 and 17 634 Euros/patient/year respectively (p<0.01), that is lower than results from Western European countries. Conclusion - Our study provides current inputs for policy making and contributes to understanding variation of costof- illness of multiple sclerosis in Europe.]

Clinical Neuroscience

[Current questions of multiple sclerosis: the secunder progressive form of the disease]


[Recent data suggest that long-term worsening is common in relapsing-remitting multiple sclerosis patients and is largely independent of relapses or new lesion formation on brain MRI. The current definition of secunder progressive multiple sclerosis is worsening of disability independent of relapses over at least 6-month interval. Early focal inflammatory disease activity and spinal cord lesion are predictors of very-long term disease outcomes in relapse - onset multiple sclerosis. The potential of PET imaging to visualize hidden inflammation in MS brain in vivo is an important contribution for better understanding the progression of the disease. Therefore, PET imaging is a promising tool in detecting the conversion from relapsing remitting multiple sclerosis to secunder progressive form of multiple sclerosis. Furthermore, neuro-axonal damage is the pathological substrate of permanent disability in different neurological disorders including multiple sclerosis. The neurofilament proteins have promise in this context because their levels rise upon neuro-axonal damage not only in the cerebrospinal fluid but also in blood. Patients with increased serum levels of neurofilament at baseline, independent of other clinical and MRI variables, experience significantly more brain and spinal cord volume loss over 2 years and 5 years of follow-up. The kynurenine-pathway abnormalities may be associated with the swich from early-mild stage multiple sclerosis to debilitating progressive forms of the disease. Analysis of these metabolites in serum may have application as multiple sclerosis disease biomarkers. Free radical action has been suggested as a causal factor in the illness. Increased free radical production and consumption of the scavenger molecules were found during the active phase of the disease. Based on the clinical findings (EXPAND Study) and pathomechanism of the disease siponimod is approved by the US Food and Drug Administration for the treatment of relapsing remitting forms of multiple sclerosis, to include secunder progressive multiple sclerosis with active disease, relapsing-remitting multiple sclerosis and clinically isolated syndrome.]

Clinical Neuroscience

[Is second-line immunomodulatory treatment effective in multiple sclerosis?]


[Purpose - Natalizumab is the first evidence based monoclonal antibody, which was launched for treatment in relapsing remitting multiple sclerosis in Hungary in 2010. Standardized follow-up is required to use it. Our aim was to evaluate the efficacy and to monitor the safety of natalizumab treatment by using an electronic database established for MS registry. Clinical activity was measured by annual relapse rates, functional status of patients measured by EDSS and MFSC. Radiological activity was evaluated by standard MRI protocol. Data, results of MS patients and side effects of natalizumab treatment were recorded in iMed software. Results - 31 patients started the natalizumab treatment after 6.5±5.8 years from the onset of MS. The efficacy of treatment was evaluated after a mean of 67 (min: 14 max: 128) infusions in December 2016. The drop-out rate was low, due to the presence of neutralising antibodies in one case, pregnancy in two cases and development of malignant disease in one case which was not related to the natalizumab treatment. The treatment was well tolerated with excellent compliance without serious side effects. The annual relapse rate reduced from a mean of 1.7 to 0.03 (p<0.000001) in the first 12 months of treatment compared to the pretreatment 12 month activity, and it stayed at low level during the whole follow up. EDSS was stable or improved with an exception of two cases. In 23 subjects (77%) lack of new/enlarging T2 lesions and lack of gadolineum-enhancing lesions on MRI were observed. 18 patients (60%) had no evidence of disease activity (NEDA-3). PASAT test improved in most of the cases. Conclusion - The natalizumab therapy was very effective in all cases including those patients who had active disease under the previous immunomodulatory treatment.]